Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Godfrey C. Chan"'
Autor:
Jaume Mora, Godfrey C. Chan, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe, Brian H. Kushner
Publikováno v:
Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Naxitamab is a humanized GD2‐binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high‐risk neuroblastoma limited to bone or bone marrow. Trial 20
Externí odkaz:
https://doaj.org/article/75154eee605545ceb3d10714c295ce08
Autor:
Jaume Mora, Godfrey C. Chan, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe, Brian H. Kushner
Publikováno v:
Cancer reports (Hoboken, N.J.)REFERENCES.
Naxitamab is a humanized GD2-binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high-risk neuroblastoma limited to bone or bone marrow. Trial 201 (NCT03363373) is an on